Idexx Laboratories Inc /De reports $1.14 billion revenue for quarter ended March 31, 2026
Idexx Laboratories Inc /De reported revenue of $1.14 billion for the quarter ended March 31, 2026.
For the same period it posted net income of $278.4 million, or $3.47 per diluted share.
That is a net margin of 24.4%.
On Sanad's AAOIFI Standard 21 screen, Idexx Laboratories Inc /De is currently compliant: interest-bearing debt is 0.7% of market capitalisation (limit 30%), and impure income is 0.1% of revenue (limit 5%).
Is Idexx Laboratories Inc /De halal?
See the full AAOIFI screening of Idexx Laboratories Inc /De
See the full AAOIFI screening of Idexx Laboratories Inc /De
Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 5, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.